SCNI
Scinai Immunotherapeutics Ltd.Company with tickers: SCNI
CIK
1611747
CUSIP
09073Q303
Shares Outstanding
13,872,899,584
Website
https://www.biondvax.com
Investor Relations
https://www.scinai.com/biondvax-is-now-scinai
13F Activity (30d)
2 filings
1 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $1,311,000 | USD | 2025-12-31 | 20-F | 2026-04-01 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $3,963,000 | USD | 2025-12-31 | 20-F | 2026-04-01 |
| Gross Profit | $-2,652,000 | USD | 2025-12-31 | 20-F | 2026-04-01 |
| Operating Expenses | $4,890,000 | USD | 2025-12-31 | 20-F | 2026-04-01 |
| Research & Development | $2,369,000 | USD | 2025-12-31 | 20-F | 2026-04-01 |
| Operating Income | $-7,542,000 | USD | 2025-12-31 | 20-F | 2026-04-01 |
| Net Income | $-8,307,000 | USD | 2025-12-31 | 20-F | 2026-04-01 |
| EPS (Basic) | $0.00 | USD/shares | 2025-12-31 | 20-F | 2026-04-01 |
| EPS (Diluted) | $0.00 | USD/shares | 2025-12-31 | 20-F | 2026-04-01 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2024-12-31 |
|---|---|
| License | $100,000 |